Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART

Archives of Virology

Volumn 155, Issue 6, 2010, Pages 895-903

  Lopez, Carlos A ^a   Vazquez, Manuel ^a   Hill, Martin D ^a   Del C Colon, Maria ^a   Porrata Doria, Tirtsa ^a   Johnston, Ian C D ^b   Lorenzo, Eric ^a,c  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b MILTENYI BIOTEC GMBH   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; FC RECEPTOR; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CHEMISTRY; DNA SEQUENCE; DRUG EFFECT; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MIDDLE AGED; MOLECULAR EVOLUTION; MONOCYTE; PHYLOGENY; PLASMA; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; EVOLUTION, MOLECULAR; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PHYLOGENY; PLASMA; RECEPTORS, IGG; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953323772     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0659-3     Document Type: Article

References (58)

1. Finzi D, Blankson J, Siliciano JD et al (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
2. Gunthard HF, Frost SD, Leigh-Brown AJ et al (1999) Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73: 9404-9412.
3. Ibanez A, Puig T, Elias J et al (1999) Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 13: 1045-1049.
4. Pomerantz RJ (2001) Residual HIV-1 infection during antiretroviral therapy: the challenge or viral persistence. AIDS 15: 1201-1211.
5. Pomerantz RJ (2003) Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 4: 137-143.
6. Pomerantz RJ (2004) Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication. Arch Immunol Ther Exp (Warsz) 52: 297-306.
7. Shen L, Siliciano RF (2008) Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122: 22-28.
8. Chun TW, Stuyver L, Mizell SB et al (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94(24): 13193-13197.
9. Finzi D, Hermankova M, Pierson T et al (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
10. Wong JK, Hezareh M, Gunthard HF et al (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
11. Hermankova M, Ray SC, Ruff C et al (2001) HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies/ml receiving combination therapy. JAMA 286: 196-207.
12. Dornadula G, Zhang H, VanUitert B et al (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282: 1627-1632.
13. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF (2007) Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 5: 95-106.
14. Kieffer TL, Finucane MM, Nettles RE et al (2004) Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189: 1452-1465.
15. Martinez-Picado J, DePasquale MP, Kartsonis N et al (2000) Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 97: 10948-10953.
16. Natarajan V, Bosche M, Metcalf JA et al (1999) HIV-1 replication in patients with undetectable plasma virus receiving HAART: highly active antiretroviral therapy. Lancet 353: 119-120.
17. Nettles RE, Kieffer TL, Kwon P et al (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
18. Sahu GK, Paar D, Frost SD et al (2009) Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 81: 9-15.
19. Tobin NH, Learn GH, Holte SE et al (2005) Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79: 9625-9634.
20. Finzi D, Plaeger SF, Dieffenbach CW (2006) Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis. Clin Vaccine Immunol 13: 715-721.
21. Kim H, Perelson AS (2006) Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comp Biol 2: 1232-1247.
22. Palmer S, Maldarelli F, Wiegand A et al (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105: 3879-3884.
23. Bailey JR, Sedaghat AR, Kieffer T et al (2006) Residual human immunodeficiency virus type 1 viremia in some patients of antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80: 6441-6457.
24. McClernon DR, Ramsey E, St Clair E (2007) Magnetic silica extraction for low-level human immunodeficiency virus type 1 genotyping. J Clin Microbiol 45: 572-574.
25. Tremblay MJ, Fortin JF, Cantin R (1998) The acquisition of host-encode proteins be nascent HIV-1. Immunol Today 189: 346-351.
26. Lawn SD, Roberts BD, Griffin GE et al (2000) Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 74: 139-145.
27. Lawn SD, Butera ST (2000) Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection. J Virol 74: 10256-10259.
28. Toossi Z, Mayanja-Kizza H, Lawn SD (2007) Dynamic variation in the cellular origin of HIV type 1 during treatment of tuberculosis in dually infected subjects. AIDS Res Hum Retrovirus 23: 93-100.
29. Lupo LD, Butera ST (2004) Application of μMACS Streptavidin MicroBeads for the analysis of HIV-1 directly from the patient plasma. MACS & More 8: 16-19.
30. Liao HX, Miller SE, Jones DM, Haynes BF (1996) Co-localization of CD44 expression with HIV budding in HIV-infected cells. Conference on Advances in AIDS Vaccine Development; National Cooperative Vaccine Development Groups for AIDS. Meeting. Conf Adv AIDS Vaccine Dev Natl Coop Vaccine Dev Groups AIDS Meet 8th 1996 Bethesda, Md. 169.
31. Suyama M, Daikoku E, Goto T et al (2009) Reactivation from latency displays HIV particle budding at plasma membrane, accompanying CD44 upregulation and recruitment. Retrovirology 6: 63.
32. Ott DE (1997) Cellular proteins in HIV virions. Red Med Virol 7: 167-180.
33. Terry VH, Johnston IC, Spina CA (2009) CD44 microbeads accelerate HIV-1 infection in T cells. Virology 388: 294-304.
34. Belair M, Dovat M, Foley B et al (2009) The polymorphic nature of HIV type 1 env V4 affects the patterns of potential N-glycosylation sites in proviral DNA at the intrahost level. AIDS Res Hum Retrovir 25(2): 199-206.
35. Castro E, Bélair M, Rizzardi GP et al (2008) Independent evolution of hypervariable regions of HIV-1 gp120: V4 as a swarm of N-Linked glycosylation variants. AIDS Res Hum Retroviruses 24(1): 106-113.
36. Lorenzo E, Herrera RJ, Lai S, Fischl MA, Hill MD (1996) The Tat and C2-V3 envelope genes in the molecular epidemiology of human immunodeficiency virus-1. Virology 221: 310-317.
37. Lorenzo E, Collins T, Fisher E, Herrera RJ (2001) The use of tat and env sequences from human immunodeficiency virus 1 in phylogenetic epidemiological studies. Electrophoresis 22: 438-444.
38. Hill MD, Lorenzo E, Kumar A et al (2004) Changes in the human immunodeficiency virus V3 region that correspond with disease progression: a meta-analysis. Virus Res 106(1): 27-33.
39. Lorenzo E, Colon MC, Almodovar S et al (2004) Influence of CD4+ T cell counts on viral evolution in HIV-infected individuals undergoing suppressive HAART. Virology 330(1): 116-126.
40. Rouet F, Chaix ML, Nerrienet E et al (2007) Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 45: 380-388.
41. Berg ES, Olaisen B (1994) Hybrid PCR sequencing: sequencing of PCR products using a universal primer. Biotechniques 17(5): 896-901.
42. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22(22): 4673-4680.
43. Higgins DG, Thompson JD, Gibson TJ (1996) Using CLUSTAL for multiple sequence alignments. Methods Enzymol 266: 383-402.
44. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41: 95-98.
45. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4. 0. Mol Biol Evol 24: 1596-1599.
46. Kimura M (1980) A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16: 111-120.
47. Felsenstein J (1985) Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39: 783-791.
48. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
49. Kuiken C, Foley B, Hahn B et al (2001) HIV sequence compendium 2001. Theoretical Biology and Biophysics Group. Los Alamos National Laboratory, Los Alamos.
50. Jensen MA, Li FS, van 't Wout AB et al (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV-1 env V3 loop sequences. J Virol 77: 13376-13388.
51. Lorenzo E, Kumar R, Hill MD et al (2004) Genetic characterization of human immunodeficiency virus type 1 Tat before and after highly active antiretroviral therapy. AIDS Res Hum Retrovir 20(10): 1108-1112.
52. Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 81: 1-9.
53. Miura T, Brumme CJ, Brockman MA et al (2009) HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 83(7): 3407-3412.
54. Stemenkovic I, Aruffo A, Amiot M, Seed B (1989) A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56: 1057-1062.
55. Bounou S, Leclerc JE, Tremblay MJ (2002) Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 76: 1004-1014.
56. Weber C, Belge KU, Von-Hundelshausen P et al (2000) Differential chemokine receptor expression and function in human monocytes subpopulation. J Leukoc Biol 67: 699-704.
57. Ellery PJ, Tippett E, Chiu YL et al (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 178: 6581-6589.
58. Kearney M, Palmer S, Maldarelli F et al (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22: 497-501.